RI_Vall_P_TA | RI_Vall_Pall | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
ST | HPH | HPD | ST | HPH | HPD | |||||||
Fixed effects | b | (SE) | b | (SE) | b | (SE) | b | (SE) | b | (SE) | b | (SE) |
intercept | 36.65*** | (6.94) | 43.69*** | (5.05) | 55.87*** | (4.44) | 48.71*** | 4.65 | 52.40*** | (3.91) | 59.42*** | (3.35) |
Vignette characteristics | ||||||||||||
Application purpose | ||||||||||||
Risk assessmentRefA | ||||||||||||
Clinical diagnostics | −0.30 | (6.24) | 6.41 | (3.53) | 5.10 | (5.05) | 2.10 | (4.17) | 3.90 | (2.70) | −2.21 | (3.80) |
Drug effect | 0.91 | (6.42) | 8.57* | (3.66) | 9.12* | (4.60) | −1.29 | (4.27) | 2.69 | (2.82) | 2.05 | (3.48) |
Early detection of a disease | −2.50 | (6.59) | 8.72* | (4.26) | 12.64** | (3.85) | 2.16 | (4.38) | 5.93 | (3.25) | 4.61 | (2.91) |
Monitoring | 5.67 | (6.39) | 8.25* | (4.17) | 11.27** | (4.16) | 6.16 | (4.28) | 2.28 | (3.21) | 3.98 | (3.15) |
Therapy diagnostics | 5.94 | (7.66) | 9.31* | (3.88) | 10.32** | (3.66) | −0.41 | (5.10) | 4.85 | (2.98) | 0.59 | (2.79) |
Seriousness of the situation | ||||||||||||
Acute and life-threateningRefB | ||||||||||||
Acute, but not life-threatening | 8.25 | (5.33) | 2.46 | (3.95) | −3.16 | (4.08) | 1.02 | (3.56) | −1.53 | (3.05) | 0.83 | (3.09) |
Chronic, but not life-threatening | 7.91 | (5.53) | 3.49 | (3.85) | 0.129 | (3.56) | 6.46 | (3.74) | 1.73 | (2.97) | 2.63 | (2.70) |
Chronic, slowly advancing and life-threatening | 2.90 | (5.48) | 5.88 | (4.28) | 1.80 | (3.96) | 1.59 | (3.64) | 6.08 | (3.27) | 3.94 | (2.96) |
Analysis and feedback | ||||||||||||
Transmitted automatically and the result is communicated in written formRefC | ||||||||||||
Transmitted automatically and only a conspicuous result is communicated by a health professional | RefC-3.44 | (5.72) | RefC-0.44 | (3.82) | ||||||||
Transmitted automatically and the result is communicated by a health professional | RefC0.23 | (5.37) | RefC0.93 | (3.60) | ||||||||
Analyzed in a laboratory and only a conspicuous result is communicated by a health professionalRefD | ||||||||||||
Analyzed automatically, and the result is displayed immediately | RefC-5.94 | (5.20) | RefD5.02 | (3.27) | RefD3.11 | (3.41) | RefC-0.38 | (3.46) | RefD5.16* | (2.49) | RefD0.96 | (2.54) |
Analyzed in a laboratory and the result is communicated in written form | RefD4.62 | (3.33) | RefD-1.80 | (3.22) | RefD3.87 | (2.54) | RefD-1.75 | (2.41) | ||||
Analyzed in a laboratory and the result is communicated by a health professional | RefD6.17 | (3.53) | RefD6.41 | (3.53) | RefD1.90 | (2.71) | RefD5.30* | (2.64) | ||||
Medical expertise of the tested person | ||||||||||||
NoRefE | ||||||||||||
Unprofessional | 5.06 | (4.88) | 0.78 | (3.15) | 1.37 | (3.07) | 2.39 | (3.24) | 1.18 | (2.41) | −0.85 | (2.30) |
Professional | 13.80** | (4.89) | 9.43** | (3.11) | 8.36** | (2.99) | 7.17* | (3.27) | 7.04** | (2.38) | 2.92 | (2.26) |
Emotional support | ||||||||||||
Not presentRefF | ||||||||||||
Potentially available | 7.46 | (4.56) | 5.44 | (3.27) | 2.72 | (3.16) | 3.76 | (3.05) | 2.54 | (2.50) | 4.11 | (2.36) |
Personally present | 8.61 | (4.81) | 9.66** | (3.13) | 0.94 | (3.63) | 3.78 | (3.19) | 4.41 | (2.41) | 4.70 | (2.72) |
Respondent characteristics | ||||||||||||
Technology affinity enthusiasm | 6.21* | (2.90) | 2.14 | (2.50) | 2.41 | (2.35) | 2.07 | (2.02) | 0.54 | (1.92) | 3.24 | (1.71) |
Technology affinity competence | 0.16 | (3.20) | 2.29 | (2.97) | −1.02 | (2.64) | 2.07 | (2.26) | 2.87 | (2.31) | −2.50 | (1.95) |
Technology affinity positive attitude | 4.04 | (3.60) | 4.79 | (3.01) | 7.29* | (3.01) | 0.17 | (2.48) | 2.11 | (2.31) | −0.43 | (2.22) |
Perceived susceptibility | 0.24 | (0.34) | 0.37 | (0.33) | 0.40 | (0.31) | ||||||
Self-efficacy | −0.04 | (0.31) | −0.51 | (0.31) | 0.07 | (0.27) | ||||||
Perceived severity | 0.16*** | (0.04) | 0.23*** | (0.04) | 0.19*** | (0.03) | ||||||
Outcome expectancy | 0.89*** | (0.05) | 0.68*** | (0.04) | 0.69*** | (0.04) | ||||||
Random effects | ||||||||||||
δim (error variance between) | 216.28 | 278.52 | 213.94 | 113.18 | 162.74 | 101.95 | ||||||
εij (error variance within) | 676.11 | 461.75 | 406.46 | 286.40 | 267.99 | 230.54 | ||||||
Deviance | 3234.43 | 4459.54 | 3974.44 | 2959.49 | 4200.21 | 3712.40 | ||||||
NO / NG | 337/183 | 478/196 | 433/192 | 337/183 | 478/196 | 433/192 |